AKT1 and non-small cell lung carcinoma: This role included MKRN2-specific inhibition of PI3Kp85α ubiquitination and degradation, thereby promoting activation of Akt signaling and suggesting MKRN2 as a candidate prognostic biomarker and possible therapeutic target in NSCLC.